Health Care Charges for Patients with Ocular Hypertension or Primary Open-angle Glaucoma

Ophthalmology

Volumn 115, Issue 4, 2008, Pages

  Pasquale, Louis R ^a   Dolgitser, Margarita ^b   Wentzloff, Jeffrey N ^a   Stern, Lee S ^b   Doyle, John J ^c   Chiang, Tina H ^c   Walt, John G ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Analytica International   (United States)

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BILLING AND CLAIMS; BLINDNESS; CALCULATION; CATARACT; CATARACT EXTRACTION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COVARIANCE; DATA BASE; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES;

EID: 41149180253     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.04.059     Document Type: Article

References (30)

1. Leibowitz H.M., Krueger D.E., Maunder L.R., et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 24 suppl (1980) 335-610
2. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713 discussion 829-30
3. Quigley H.A., and Broman A.T. The number of people worldwide with glaucoma in 2010 and 2020. Br J Ophthalmol 90 (2006) 262-267
4. Distelhorst J.S., and Hughes G.M. Open-angle glaucoma. Am Fam Physician 67 (2003) 1937-1944
5. Traverso C.E., Walt J.G., Kelly S.P., et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 89 (2005) 1245-1249
6. Mills R.P., Budenz D.L., Lee P.P., et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol 141 (2006) 24-30
7. Gieser D.K., Tracy Williams R., O'Connell W., et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma 15 (2006) 419-425
8. Kymes S.M., Kass M.A., Anderson D.R., et al. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 141 (2006) 997-1008
9. Vold S.D., Wiggins D.A., and Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma 9 (2000) 150-153
10. Fiscella R.G., Green A., Patuszynski D.H., and Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 136 (2003) 18-25
11. Mick A.B., Gonzalez S., Dunbar M.T., and McSoley J.J. A cost analysis of the prostaglandin analogs. Optometry 73 (2002) 614-619
12. Day D.G., Schacknow P.N., Sharpe E.D., et al. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 20 (2004) 383-392
13. Tuil E., Hommer A.B., Poulsen P.B., et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients-a European perspective. Int J Clin Pract 59 (2005) 1011-1016
14. Noecker R.J., and Walt J.G. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 141 suppl (2006) S15-S21
15. Fiscella R., and Walt J. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension. Drugs Aging 23 (2006) 39-47
16. De Natale R., Draghi E., and Dorigo M.T. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications. Acta Ophthalmol Scand 82 (2004) 393-396
17. Medeiros F.A., Weinreb R.N., Sample P.A., et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol 123 (2005) 1351-1360
18. Mansberger S.L. A risk calculator to determine the probability of glaucoma. J Glaucoma 13 (2004) 345-347
19. Washington University in St. Louis School of Medicine. Glaucoma 5-year risk estimator. http://ohts.wustl.edu/risk Accessed November 15, 2006
20. ICD-9-CM International Classification of Diseases, 9th Revision: Clinical Modification. 5th ed. (1999), Medicode, Salt Lake City Vols. 1-3
21. U.S. Department of Labor, Bureau of Labor Statistics. Consumer price index-all urban consumers. U.S. medical care (CUUR0000SAM). http://data.bls.gov/cgi-bin/surveymost?cu Accessed October 16, 2006.
22. Dang D.K., Pont J.M., and Portmoy M.A. Episode treatment groups: an illness classification and episode building system-part II. Med Interface 9 (1996) 122-128
23. Finfacts Reports/Services. Global income per capita-published 2006, from World Bank Development Indicators 2006. http://www.finfacts.ie/biz10/globalworldincomepercapita.htm Accessed January 30, 2007
24. Lindblom B., Nordmann J.P., Sellem E., et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 84 (2006) 74-83
25. Bertakis K.D., Azari R., Helms L.J., et al. Gender differences in the utilization of health care services. J Fam Pract 49 (2000) 147-152
26. Hodgson T.A., and Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care 39 (2001) 599-615
27. Fenter T.C., Naslund M.J., Shah M.B., et al. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care 12 suppl (2006) S90-S98
28. Javitt J.C., and Aiello L.P. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124 (1996) 164-169
29. Rouland J., Berdeaux G., and Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging 22 (2005) 315-321
30. Oostenbrink J.B., Rutten-van Molken M.P., and Sluyter-Opdenoordt T.S. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 10 (2001) 184-191